
PD-L1 status may not be the best predictor when it comes to determining who will respond to checkpoint blockade.

PD-L1 status may not be the best predictor when it comes to determining who will respond to checkpoint blockade.

Genetic mutations that were previously associated with breast and ovarian cancer also have implications for men with prostate cancer.

Oncology nurses are crucial in the management of cancer symptoms and treatment-related adverse events.

Many patients with cancer are prescribed opioids to manage post-surgical pain, putting oncology professionals in a prime position to affect the current epidemic.

Not many people knew about male breast cancer when Sam Rivera was diagnosed, but he took the information from his nurses to spread awareness about the disease.



Empathy and cultural competency are two vital traits for an oncology nurse to have.

All patients with myeloma should be treated for bone disease.

Each type of cancer treatment has its own adverse event (AE) profile, and BRAF and MEK inhibitors are no different.

CAR T-cell therapy is producing durable responses in many subgroups of patients. However, the treatment could also come with some major adverse events.

There are some adverse events that are common to all PARP inhibitors, and others that are specific to each drug.

Combining two checkpoint blockades can be very efficacious in treating metastatic melanoma, but the benefits come with increased risk of adverse events, too.


Managing immune-related adverse events is different from managing the effects of chemotherapy.

The recent approval of ibrutinib plus obinutuzumab is a major advancement in the chronic lymphocytic leukemia space.

Registered pharmacist Jamie Fritz, RPh, Oral Pharmacy Manager, Compass Oncology, describes the vital role that oral oncology nurses play in cancer care.


Howard Cohen, RPh, MS, FASHP, director of oncology pharmacy services, Smilow Cancer Center, Yale New Haven Health, discusses the challenges of cancer treatment from a pharmacy perspective.


Kathy Oubre, MS, Chief Operating Officer, Pontchartrain Cancer Center in Covington, Louisiana, shares some barriers to adherence to oral oncolytics that patients may face.

With the inception of its Precision Cancer Therapies Program, the Ochsner Cancer Institute has been able to expand availability of early phase clinical trials to patients who might otherwise have had to drive up to 5 or 6 hours to participate in one.

As part of an ambitious plan to transform the culture at Vidant Health and improve the experience of patients and team members alike, Oehlert helped reframe the organization’s goals to consider kindness and compassion as part of strategic excellence.

Tiki Barber, former NFL running back and radio host, explains how he feels about oncology nurses, who helped his mother through her breast cancer experience.

Nurses can take part in turning the tide against the disease.

Ascertaining family history and promoting screening are key.

John Marshall, MD, explains that health care providers need to retool their thinking when young people present with GI complaints, and be open to the possibility that these could indicate colon cancer.

Nurses can help coach and push patients and their physicians along to do the steps that are needed to get good screening, says John Marshall, MD.

In just over 5 years, the growth and development in the field of breast cancer have been astronomical. Julie Nangia, MD, Assistant Professor of Medicine, Baylor College of Medicine, discusses the recent explosion of knowledge about non-BRCA genes, and the significant progress in therapies targeted to BRCA mutation carriers.

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, discusses the work ahead in the ovarian cancer field.